Managing unusual sensory experiences in at-risk mental state for psychosis in England: A parallel group, single-blind, randomised controlled feasibility trial

Young people at risk of psychosis often present to services with unusual sensory experiences (USE). Managing Unusual Sensory Experiences (MUSE) is a digital intervention that therapists can use with clients to support better understanding of these experiences and how to manage them. This study aimed to test the feasibility of delivering MUSE within a RCT design. We conducted a randomised, single-blind, feasibility study of MUSE + Treatment as Usual (TAU), compared to TAU, for individuals experiencing USE in At-Risk Mental State (ARMS) services across two mental health trusts in England. Assessments were conducted at baseline, 12 weeks (post-treatment), and 20 weeks (follow-up). Ninety-three people were randomised (47 to TAU and 46 to MUSE+TAU). 79 % of participants completed the primary outcome measures at the primary timepoint (post-treatment). For the primary outcomes, the functioning (SOFAS) score at 12 weeks favoured MUSE+TAU (SOFAS adjusted mean difference 4·19 [95 % CI:10·22 to 1·85] with a Cohen's d of -0·28 [95 % CI:0·68 to 0·12]) and further improved at 20 weeks (adjusted mean difference -5·33 [95 % CI:11·65 to 1·0]; Cohen's d -0·35 [95 % CI:0·77 to 0·07]). The other primary outcome measure (PSYRATS-AH) explored impact on USE and found no difference at 12 weeks (mean adjusted difference 0·01 [95 % CI:4·88 to 4·87], Cohen's d 0·00 [95 % CI:0·48 to 0·48]), but slightly favoured TAU at 20 weeks (adjusted mean difference -1·43 [95 % CI:6·53 to 3·66], Cohen's d -0·14 [95 % CI:0·64 to 0·36]). MUSE is a promising intervention for therapists to use in support of individuals at risk of psychosis.

Authors

Institutions

Publication Details

Journal
Psychiatry Research
Published
2025-05-24
DOI
https://doi.org/10.1016/j.psychres.2025.116564
Citations
4
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
5.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Managing unusual sensory experiences in at-risk mental state for psychosis in England: A parallel group, single-blind, randomised controlled feasibility trial

Nicola L. Barclay, Charles Fernyhough, Robert Dudley, Guy Dodgson et al.
4 citations
Psychiatry Research
Schizophrenia research and treatment
5.88
article

Managing unusual sensory experiences in at-risk mental state for psychosis in England: A parallel group, single-blind, randomised controlled feasibility trial

Nicola L. Barclay, Charles Fernyhough, Robert Dudley, Guy Dodgson, Jochen Einbeck, Jahnese Hamilton, Toby Brandon, Akansha Singh, C.A. Boyle, Jenny Simpson, Lauren Birkett, Chris Gibbs, Vickie Larry
article en
4 citations

Abstract

Young people at risk of psychosis often present to services with unusual sensory experiences (USE). Managing Unusual Sensory Experiences (MUSE) is a digital intervention that therapists can use with clients to support better understanding of these experiences and how to manage them. This study aimed to test the feasibility of delivering MUSE within a RCT design. We conducted a randomised, single-blind, feasibility study of MUSE + Treatment as Usual (TAU), compared to TAU, for individuals experiencing USE in At-Risk Mental State (ARMS) services across two mental health trusts in England. Assessments were conducted at baseline, 12 weeks (post-treatment), and 20 weeks (follow-up). Ninety-three people were randomised (47 to TAU and 46 to MUSE+TAU). 79 % of participants completed the primary outcome measures at the primary timepoint (post-treatment). For the primary outcomes, the functioning (SOFAS) score at 12 weeks favoured MUSE+TAU (SOFAS adjusted mean difference 4·19 [95 % CI:10·22 to 1·85] with a Cohen's d of -0·28 [95 % CI:0·68 to 0·12]) and further improved at 20 weeks (adjusted mean difference -5·33 [95 % CI:11·65 to 1·0]; Cohen's d -0·35 [95 % CI:0·77 to 0·07]). The other primary outcome measure (PSYRATS-AH) explored impact on USE and found no difference at 12 weeks (mean adjusted difference 0·01 [95 % CI:4·88 to 4·87], Cohen's d 0·00 [95 % CI:0·48 to 0·48]), but slightly favoured TAU at 20 weeks (adjusted mean difference -1·43 [95 % CI:6·53 to 3·66], Cohen's d -0·14 [95 % CI:0·64 to 0·36]). MUSE is a promising intervention for therapists to use in support of individuals at risk of psychosis.

Psychiatry ResearchVol. 351
Durham University (GB), Cumbria Northumberland Tyne and Wear NHS Foundation Trust (GB), Northumbria University (GB), Department of Mathematical Sciences (RU), Tees, Esk and Wear Valleys NHS Foundation Trust (GB)
National Institute for Health and Care Research, Research for Patient Benefit Programme
Gender equality
Openalex Percentile: Top 4%
Schizophrenia research and treatment
5.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.